Hirata, Kenro

写真a

Affiliation

School of Medicine, Cancer Center （Shinanomachi）

Position

Instructor

E-mail Address

E-mail address

Page Top ▲

Academic Background 【 Display / hide 】

  • 2001.04
    -
    2007.03

    Keio University, 医学部

    University

  • 2009.04
    -
    2013.03

    Keio University, 医学研究科

    Graduate School, Doctoral course

Page Top ▲

Academic Degrees 【 Display / hide 】

  • 博士（医学）, Keio University, Coursework, 2014.02

Page Top ▲

Licenses and Qualifications 【 Display / hide 】

  • Fellow of the Japanese Society of Internal Medicine, 2019

  • Diplomate, Subspecialty Board of Medical Oncology, JSMO

  • 日本がん治療認定医機構　がん治療認定医

  • 日本ヘリコバクター学会　H. pylori感染症認定医

  • 日本肝臓学会　肝臓専門医

display all >>

Page Top ▲
 

Research Areas 【 Display / hide 】

  • Gastroenterology

Page Top ▲

Research Keywords 【 Display / hide 】

  • 消化器系悪性腫瘍

  • 胃癌

  • 食道癌

Page Top ▲
 

Papers 【 Display / hide 】

  • Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology Group

    Hirata K., Hamamoto Y., Ando M., Imamura C.K., Yoshimura K., Yamazaki K., Hironaka S., Muro K.

    BMC cancer （BMC cancer)  20 （ 1 ）  2020.06

    　View Summary

    BACKGROUND: Ramucirumab (RAM) with weekly paclitaxel (wPTX) is a standard second-line therapy for advanced or recurrent gastric cancer. Nanoparticle albumin-bound paclitaxel (nab-PTX), an albumin-bound form of PTX, was developed to improve the therapeutic index of taxane treatment. However, the ABSOLUTE trial showed the non-inferiority of weekly nab-PTX (w-nab-PTX) to wPTX with respect to overall survival (OS) as second-line therapy for advanced or recurrent gastric cancer, and subgroup analysis of patients with peritoneal dissemination showed favourable OS and progression-free survival (PFS) in the w-nab-PTX arm compared to those in the wPTX arm. This study evaluated whether w-nab-PTX plus RAM is more effective than wPTX plus RAM for patients with peritoneal dissemination. METHODS: The P-SELECT trial (WJOG10617G) is a prospective, open-label, multicentre, randomised phase II study evaluating wPTX plus RAM (arm A) versus w-nab-PTX plus RAM (arm B). Key eligibility criteria include the following: 1) histologically proven adenocarcinoma, 2) unresectable or recurrent gastric cancer, 3) peritoneal dissemination, 4) intolerance or refractory to first-line therapy including fluoropyrimidines, and 5) ECOG Performance Status (PS) 0-2. Patients are randomised to either arm at a 1:1 ratio stratified by institution, PS, and severity of ascites. PTX (80 mg/m2; days 1, 8, and 15) and RAM (8 mg/kg; days 1 and 15) are administered every 4 weeks in arm A, while nab-PTX (100 mg/m2; days 1, 8, and 15) instead of PTX is administered in arm B. The primary endpoint is OS, and the main secondary endpoints are PFS, objective response rate, safety, neuropathy-specific quality of life, and biomarkers. To maintain a probability of ≥70% to ensure the hazard ratio for OS in arm B is lower than 0.90, 105 subjects are required. The study was initiated in October 2018 and is being conducted in 58 centres of the West Japan Oncology Group. DISCUSSION: The results of this study will determine whether w-nab-PTX plus RAM has the potential to be a preferred therapeutic option for advanced and recurrent gastric cancer with peritoneal dissemination, compared to wPTX plus RAM. TRIAL REGISTRATION: This study was prospectively registered in the Japan Registry of Clinical Trials (jRCTs031180022, October 1, 2018).

  • Clinical and Endoscopic Characteristics of Pyogenic Granuloma in the Small Intestine: A Case Series with Literature Review

    Hayashi Y., Hosoe N., Takabayashi K., Kamiya K.J.L., Mutaguchi M., Miyanaga R., Hirata K., Fukuhara S., Mikami Y., Sujino T., Masugi Y., Naganuma M., Ogata H., Kanai T.

    Internal medicine (Tokyo, Japan) （Internal medicine (Tokyo, Japan))  59 （ 4 ） 501 - 505 2020.02

    ISSN  09182918

    　View Summary

    Pyogenic granuloma (PG) generally appears in the skin or oral cavity, but rarely occurs in the small intestine, where it can cause bleeding. To date, only 35 cases of small intestinal PG have been reported in the English literature. We retrospectively collected information from the clinical records of seven cases of small intestinal PG that were managed in our hospital and summarized the characteristics. Further information on the clinical characteristics was obtained from the literature. Capsule endoscopy, useful for identifying the source of hemorrhage in obscure gastrointestinal bleeding, can detect PGs. Treatment can often be accomplished with endoscopic mucosal resection.

  • Pancreatic fat content may increase the risk of imaging progression in low-risk branch duct intraductal papillary mucinous neoplasm

    Kashiwagi K., Minami K., Seino T., Hirata K., Iwasaki E., Inoue N., Iwao Y., Kanai T.

    Journal of Digestive Diseases （Journal of Digestive Diseases)  20 （ 10 ） 557 - 562 2019.10

    ISSN  17512972

    　View Summary

    © 2019 Chinese Medical Association Shanghai Branch, Chinese Society of Gastroenterology, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine and John Wiley & Sons Australia, Ltd Objective: To identify risk factors of imaging progression (increase in cyst size or main pancreatic duct size, or a new mural nodule) in low-risk branch duct intraductal papillary mucinous neoplasm (BD-IPMN), including obesity-related factors such as pancreatic fat content. Methods: Our hospital databases were searched for patients who had completed health checkup, including upper abdominal magnetic resonance imaging (MRI) over 48 months (August 2012 to July 2016). Individuals with BD-IPMN without worrisome features and high-risk stigmata who underwent surveillance with at least one follow-up MRI, irrespective of the follow-up period, were included. Pancreatic computed tomography attenuation indexes were defined as the difference between the pancreas and spleen attenuation (P - S) and the pancreas to spleen attenuation ratio (P/S). Results: Among 75 patients diagnosed as having low-risk BD-IPMN, during a median follow-up of 36 months, 11 (15%) had imaging progression in cyst size, including two with worrisome features. A multivariate logistic analysis showed that the initial cyst size and both indexes (P - S, or P/S) were significantly associated with imaging progression in IPMN, respectively (Model 1: odds ratio [OR] 1.188, 95% confidence interval [CI] 1.060-1.331, P = 0.003; OR 0.871, 95% CI 0.776-0.977, P = 0.019; Model 2: OR 1.186, 95% CI 1.064-1.322, P = 0.002; OR 0.002, 95% CI 0.000-0.970, P = 0.049). Conclusions: Pancreatic fat content and initial cyst size were significantly associated with imaging progression in low-risk BD-IPMN. Revisions of international consensus Fukuoka guidelines might be customized based on initial cyst size and pancreatic fat content.

  • Unmet needs of cancer patients with chemotherapy-related hand-foot syndrome and targeted therapy-related hand-foot skin reaction: A qualitative study

    Komatsu H., Yagasaki K., Hirata K., Hamamoto Y.

    European Journal of Oncology Nursing （European Journal of Oncology Nursing)  38   65 - 69 2019.02

    ISSN  14623889

    　View Summary

    © 2018 Purpose: The objective of this qualitative study was to understand the perceived needs of advanced-stage cancer patients with chemotherapy-related hand-foot syndrome (HFS) and/or targeted therapy-related hand-foot skin reaction (HFSR). Method: Face-to-face interviews were conducted with 20 outpatients with advanced/recurrent cancer and chemotherapy-related HFS and/or targeted therapy-related HFSR using a semi-structured interview guide at Keio University Hospital, Tokyo, Japan. Thematic analysis was used to analyse the data. Results: The unmet needs of cancer patients with chemotherapy-related HFS and/or targeted therapy-related HFSR was identified through four themes: a sense of helplessness with persistent symptoms, noticeable appearance as a barrier to social participation, decreased willingness to work and continue treatment, and need of individual coping strategies. Conclusion: This study revealed unmet needs of cancer patients with chemotherapy-related HFS and/or targeted therapy-related HFSR that are not often voiced. Health care providers should provide full information in advance and find the best coping strategy for individual patients.

  • 集学的治療を要する頸部食道がん

    平田　賢郎

    内科 123 （ 4 ） 549 - 550 2019

    Research paper (scientific journal), Single Work, Except for reviews

display all >>

Page Top ▲

Papers, etc., Registered in KOARA 【 Display / hide 】

Page Top ▲

Presentations 【 Display / hide 】

  • Randomized phase II trial of weekly paclitaxel + ramucirumab versus weekly nab-paclitaxel + ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy: WJOG10617G/P-SELECT.

    Kenro Hirata, Yasuo Hamamoto, Kenji Tsuchihashi, Chihiro Kondoh, Kentaro Yamazaki, Shuichi Hironaka, Masahiko Ando, Chiyo K Imamura, Kenichi Yoshimura, Kei Muro

    The European Society for Medical Oncology Cancer Congress 2019, 2019.09, Poster (general)

  • 咽頭メラノーシスの視認は上気道消化管新生物予測に有用である

    Kenro Hirata

    第15回日本臨床腫瘍学会学術集会, 2017.07

  • Soft palatal melanosis as a predictor for neoplasia in the upper aerodigestive tract.

    Kenro Hirata

    American Society of Clinical Oncology 2017, 2017.06

  • 上気道消化管新生物予測における咽頭メラノーシスの有用性の検討

    Kenro Hirata

    アルコール医学生物学研究会, 2017.01, Oral Presentation(general)

  • ダクラタスビル・アスナプレビル療法における肝機能障害の検討

    Hirata Kenro

    ウイルス肝炎学術講演会, 2014.12

display all >>

Page Top ▲

Research Projects of Competitive Funds, etc. 【 Display / hide 】

  • Vulnerable高齢食道扁平上皮癌患者に対する標準治療の確立

    2020.04
    -
    2023.03

    平田　賢郎, Research grant, Principal Investigator

  • WJOG10617G フッ化ピリミジン系薬剤を含む一次治療に不応・不耐となった腹膜播種を有する切除不能の進行・再発胃/食道胃接合部腺癌に対するweekly PTX＋ramucirumab療法とweekly nab-PTX＋ramucirumab療法のランダム化第II相試験（P-SELECT試験）

    2018.10
    -
    2023.09

    平田　賢郎, Research grant, Principal Investigator

  • 標準療法不耐の高齢食道癌患者に対するオーダーメイド医療の基盤構築

    2016.04
    -
    2020.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, 平田　賢郎, Grant-in-Aid for Scientific Research (C), Principal Investigator

  • ピロリ菌感染時における十二指腸上皮細胞の鉄吸収異常と鉄毒性に関する検討

    2011
    -
    2012

    Research grant, Principal Investigator

  • ヒト鉄代謝ホルモンヘプシジンに注目したHelicobacter pylori感染十二指腸上皮細胞における鉄吸収システムの変化

    2010
    -
    2011

    平田　賢郎, Research grant, Principal Investigator

display all >>

Page Top ▲

Awards 【 Display / hide 】

  • J-HOPE award

    2019.03, The University of Texas MD Anderson Cancer Center

    Type of Award： Awards of Publisher, Newspaper Company and Foundation

  • 内科学教室同窓会　松木康夫賞

    2018.06

  • 第８回 ICAT publication award

    2013.12

  • 第７回 ICAT award 最優秀賞

    2012.12

  • サイトプロテクション研究会奨励賞

    2012.03

Page Top ▲
 

Courses Taught 【 Display / hide 】

  • 医学概論

    2020, Spring Semester, Major subject, Lecture, Within own ｆaculty

  • 医学概論

    2019, Spring Semester, Major subject, Lecture, Within own ｆaculty

  • 医学概論

    2018, Spring Semester, Major subject, Lecture, Within own ｆaculty

Page Top ▲
 

Social Activities 【 Display / hide 】

  • 特定臨床研究への対応の実際

    西日本がん研究機構（WJOG）

    2020.05

  • 大阪オンコロジーセミナー Meeting the Cancer Experts 2020 食道癌

    西日本がん研究機構（WJOG）

    2020.04

  • 特定臨床研究への対応の実際

    西日本がん研究機構（WJOG）

    2019
Page Top ▲

Committee Experiences 【 Display / hide 】

  • 2019
    -
    Present

    食道癌診療ガイドライン　システマティックレビュアー

  • 2019
    -
    Present

    JCOG（日本臨床腫瘍研究グループ）食道がんグループ　医学審査員

  • 2019
    -
    Present

    西日本がん研究機構（WJOG）臓器横断的ワーキンググループ　委員

  • 2019
    -
    Present

    胃癌治療ガイドライン システマティックレビュアー

  • 2018
    -
    Present

    西日本がん研究機構（WJOG）消化器グループ　若手会FLAG 代表委員, WJOG（西日本がん研究機構）

Page Top ▲